Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation

Marco Peviani, Eleonora Salvaneschi, Leonardo Bontempi, Alessandro Petese, Antonio Manzo, Daniela Rossi, Mario Salmona, Simona Collina, Paolo Bigini, Daniela Curti

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

The identification of novel molecular targets crucially involved in motor neuron degeneration/survival is a necessary step for the development of hopefully more effective therapeutic strategies for amyotrophic lateral sclerosis (ALS) patients. In this view, S1R, an endoplasmic reticulum (ER)-resident receptor with chaperone-like activity, has recently attracted great interest. S1R is involved in several processes leading to acute and chronic neurodegeneration, including ALS pathology. Treatment with the S1R agonist PRE-084 improves locomotor function and motor neuron survival in presymptomatic and early symptomatic mutant SOD1-G93A ALS mice. Here, we tested the efficacy of PRE-084 in a model of spontaneous motor neuron degeneration, the wobbler mouse (wr) as a proof of concept that S1R may be regarded as a key therapeutic target also for ALS cases not linked to SOD1 mutation. Increased staining for S1R was detectable in morphologically spared cervical spinal cord motor neurons of wr mice both at early (6th week) and late (12th week) phases of clinical progression. S1R signal was also detectable in hypertrophic astrocytes and reactive microglia of wr mice. Chronic treatment with PRE-084 (three times a week, for 8. weeks), starting at symptom onset, significantly increased the levels of BDNF in the gray matter, improved motor neuron survival and ameliorated paw abnormality and grip strength performance. In addition, the treatment significantly reduced the number of reactive astrocytes whereas, that of CD11b. + microglial cells was increased. A deeper evaluation of microglial markers revealed significant increased number of cells positive for the pan-macrophage marker CD68 and of CD206. + cells, involved in tissue restoration, in the white matter of PRE-084-treated mice. The mRNA levels of TNF-α and IL-1β were not affected by PRE-084 treatment. Thus, our results support pharmacological manipulation of S1R as a promising strategy to cure ALS and point to increased availability of growth factors and modulation of astrocytosis and of macrophage/microglia as part of the mechanisms involved in S1R-mediated neuroprotection.

Original languageEnglish
Pages (from-to)218-232
Number of pages15
JournalNeurobiology of Disease
Volume62
DOIs
Publication statusPublished - 2014

Fingerprint

Motor Neuron Disease
Neuroprotective Agents
Amyotrophic Lateral Sclerosis
Motor Neurons
Mutation
Nerve Degeneration
Microglia
Astrocytes
Macrophages
Therapeutics
Gliosis
2-(4-morpholino)ethyl-1-phenylcyclohexane-1-carboxylate
sigma-1 receptor
Brain-Derived Neurotrophic Factor
Hand Strength
Interleukin-1
Endoplasmic Reticulum
Intercellular Signaling Peptides and Proteins
Cell Count
Pharmacology

Keywords

  • BDNF
  • Motor neurons
  • Neurodegeneration
  • Reactive gliosis
  • Sigma-1 receptor
  • Wobbler

ASJC Scopus subject areas

  • Neurology

Cite this

Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation. / Peviani, Marco; Salvaneschi, Eleonora; Bontempi, Leonardo; Petese, Alessandro; Manzo, Antonio; Rossi, Daniela; Salmona, Mario; Collina, Simona; Bigini, Paolo; Curti, Daniela.

In: Neurobiology of Disease, Vol. 62, 2014, p. 218-232.

Research output: Contribution to journalArticle

Peviani, Marco ; Salvaneschi, Eleonora ; Bontempi, Leonardo ; Petese, Alessandro ; Manzo, Antonio ; Rossi, Daniela ; Salmona, Mario ; Collina, Simona ; Bigini, Paolo ; Curti, Daniela. / Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation. In: Neurobiology of Disease. 2014 ; Vol. 62. pp. 218-232.
@article{732230f88d014ffc82d6ab231212a5e3,
title = "Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation",
abstract = "The identification of novel molecular targets crucially involved in motor neuron degeneration/survival is a necessary step for the development of hopefully more effective therapeutic strategies for amyotrophic lateral sclerosis (ALS) patients. In this view, S1R, an endoplasmic reticulum (ER)-resident receptor with chaperone-like activity, has recently attracted great interest. S1R is involved in several processes leading to acute and chronic neurodegeneration, including ALS pathology. Treatment with the S1R agonist PRE-084 improves locomotor function and motor neuron survival in presymptomatic and early symptomatic mutant SOD1-G93A ALS mice. Here, we tested the efficacy of PRE-084 in a model of spontaneous motor neuron degeneration, the wobbler mouse (wr) as a proof of concept that S1R may be regarded as a key therapeutic target also for ALS cases not linked to SOD1 mutation. Increased staining for S1R was detectable in morphologically spared cervical spinal cord motor neurons of wr mice both at early (6th week) and late (12th week) phases of clinical progression. S1R signal was also detectable in hypertrophic astrocytes and reactive microglia of wr mice. Chronic treatment with PRE-084 (three times a week, for 8. weeks), starting at symptom onset, significantly increased the levels of BDNF in the gray matter, improved motor neuron survival and ameliorated paw abnormality and grip strength performance. In addition, the treatment significantly reduced the number of reactive astrocytes whereas, that of CD11b. + microglial cells was increased. A deeper evaluation of microglial markers revealed significant increased number of cells positive for the pan-macrophage marker CD68 and of CD206. + cells, involved in tissue restoration, in the white matter of PRE-084-treated mice. The mRNA levels of TNF-α and IL-1β were not affected by PRE-084 treatment. Thus, our results support pharmacological manipulation of S1R as a promising strategy to cure ALS and point to increased availability of growth factors and modulation of astrocytosis and of macrophage/microglia as part of the mechanisms involved in S1R-mediated neuroprotection.",
keywords = "BDNF, Motor neurons, Neurodegeneration, Reactive gliosis, Sigma-1 receptor, Wobbler",
author = "Marco Peviani and Eleonora Salvaneschi and Leonardo Bontempi and Alessandro Petese and Antonio Manzo and Daniela Rossi and Mario Salmona and Simona Collina and Paolo Bigini and Daniela Curti",
year = "2014",
doi = "10.1016/j.nbd.2013.10.010",
language = "English",
volume = "62",
pages = "218--232",
journal = "Neurobiology of Disease",
issn = "0969-9961",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation

AU - Peviani, Marco

AU - Salvaneschi, Eleonora

AU - Bontempi, Leonardo

AU - Petese, Alessandro

AU - Manzo, Antonio

AU - Rossi, Daniela

AU - Salmona, Mario

AU - Collina, Simona

AU - Bigini, Paolo

AU - Curti, Daniela

PY - 2014

Y1 - 2014

N2 - The identification of novel molecular targets crucially involved in motor neuron degeneration/survival is a necessary step for the development of hopefully more effective therapeutic strategies for amyotrophic lateral sclerosis (ALS) patients. In this view, S1R, an endoplasmic reticulum (ER)-resident receptor with chaperone-like activity, has recently attracted great interest. S1R is involved in several processes leading to acute and chronic neurodegeneration, including ALS pathology. Treatment with the S1R agonist PRE-084 improves locomotor function and motor neuron survival in presymptomatic and early symptomatic mutant SOD1-G93A ALS mice. Here, we tested the efficacy of PRE-084 in a model of spontaneous motor neuron degeneration, the wobbler mouse (wr) as a proof of concept that S1R may be regarded as a key therapeutic target also for ALS cases not linked to SOD1 mutation. Increased staining for S1R was detectable in morphologically spared cervical spinal cord motor neurons of wr mice both at early (6th week) and late (12th week) phases of clinical progression. S1R signal was also detectable in hypertrophic astrocytes and reactive microglia of wr mice. Chronic treatment with PRE-084 (three times a week, for 8. weeks), starting at symptom onset, significantly increased the levels of BDNF in the gray matter, improved motor neuron survival and ameliorated paw abnormality and grip strength performance. In addition, the treatment significantly reduced the number of reactive astrocytes whereas, that of CD11b. + microglial cells was increased. A deeper evaluation of microglial markers revealed significant increased number of cells positive for the pan-macrophage marker CD68 and of CD206. + cells, involved in tissue restoration, in the white matter of PRE-084-treated mice. The mRNA levels of TNF-α and IL-1β were not affected by PRE-084 treatment. Thus, our results support pharmacological manipulation of S1R as a promising strategy to cure ALS and point to increased availability of growth factors and modulation of astrocytosis and of macrophage/microglia as part of the mechanisms involved in S1R-mediated neuroprotection.

AB - The identification of novel molecular targets crucially involved in motor neuron degeneration/survival is a necessary step for the development of hopefully more effective therapeutic strategies for amyotrophic lateral sclerosis (ALS) patients. In this view, S1R, an endoplasmic reticulum (ER)-resident receptor with chaperone-like activity, has recently attracted great interest. S1R is involved in several processes leading to acute and chronic neurodegeneration, including ALS pathology. Treatment with the S1R agonist PRE-084 improves locomotor function and motor neuron survival in presymptomatic and early symptomatic mutant SOD1-G93A ALS mice. Here, we tested the efficacy of PRE-084 in a model of spontaneous motor neuron degeneration, the wobbler mouse (wr) as a proof of concept that S1R may be regarded as a key therapeutic target also for ALS cases not linked to SOD1 mutation. Increased staining for S1R was detectable in morphologically spared cervical spinal cord motor neurons of wr mice both at early (6th week) and late (12th week) phases of clinical progression. S1R signal was also detectable in hypertrophic astrocytes and reactive microglia of wr mice. Chronic treatment with PRE-084 (three times a week, for 8. weeks), starting at symptom onset, significantly increased the levels of BDNF in the gray matter, improved motor neuron survival and ameliorated paw abnormality and grip strength performance. In addition, the treatment significantly reduced the number of reactive astrocytes whereas, that of CD11b. + microglial cells was increased. A deeper evaluation of microglial markers revealed significant increased number of cells positive for the pan-macrophage marker CD68 and of CD206. + cells, involved in tissue restoration, in the white matter of PRE-084-treated mice. The mRNA levels of TNF-α and IL-1β were not affected by PRE-084 treatment. Thus, our results support pharmacological manipulation of S1R as a promising strategy to cure ALS and point to increased availability of growth factors and modulation of astrocytosis and of macrophage/microglia as part of the mechanisms involved in S1R-mediated neuroprotection.

KW - BDNF

KW - Motor neurons

KW - Neurodegeneration

KW - Reactive gliosis

KW - Sigma-1 receptor

KW - Wobbler

UR - http://www.scopus.com/inward/record.url?scp=84886816838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886816838&partnerID=8YFLogxK

U2 - 10.1016/j.nbd.2013.10.010

DO - 10.1016/j.nbd.2013.10.010

M3 - Article

C2 - 24141020

AN - SCOPUS:84886816838

VL - 62

SP - 218

EP - 232

JO - Neurobiology of Disease

JF - Neurobiology of Disease

SN - 0969-9961

ER -